A study to evaluate the safety, tolerability and distribution of TB0010 in head and neck squamous cell carcinoma

2024-517779-19-00 Protocol TB-H-01 Human pharmacology (Phase I) - First administration to humans Ended

Start 5 Jan 2024 · End 1 Dec 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol TB-H-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 6
Countries 1
Sites 1

EGFR-Positive Head and Neck Squamous Cell Carcinoma

Key facts

Sponsor
Tenboron Oy
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
5 Jan 2024 → 1 Dec 2025
Decision date (initial)
2024-10-22
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-517779-19-00
EudraCT number
2019-000273-22

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

EGFR-Positive Head and Neck Squamous Cell Carcinoma

VersionLevelCodeTermSystem organ class
26.1 PT 10060121 Squamous cell carcinoma of head and neck 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Tenboron Oy

Sponsor organisation
Tenboron Oy
Address
Viikinkaari 6
City
Helsinki
Postcode
00790
Country
Finland

Scientific contact point

Organisation
Tenboron Oy
Contact name
Chief Executive Officer

Public contact point

Organisation
Tenboron Oy
Contact name
Main office

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Finland Ended 6 1
Rest of world 0

Investigational sites

Finland

1 site · Ended
HUS-Yhtymae
Korva-, nenä- ja kurkkutautien klinikka, Kasarmikatu 11-13, 00130, Helsinki

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Finland 2024-01-05 2024-04-10

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-10 Finland Acceptable
2024-10-22
2024-10-22
2 SUBSTANTIAL MODIFICATION SM-1 2025-02-19 Finland Acceptable
2025-03-24
2025-03-25
3 SUBSTANTIAL MODIFICATION SM-2 2025-04-29 Finland Acceptable
2025-07-07
2025-07-07
4 SUBSTANTIAL MODIFICATION SM-3 2025-09-18 Finland Acceptable
2025-10-02
2025-10-02